Watch Demo

Italy Antidiabetics Industry Outlook 2024 - 2028

See how Italy Antidiabetics performed compared to key markets such as Canada and Australia.

Key Market Indicators

Italian diabetes medicine sales are projected to reach $1.6 billion by 2028, up from $1.5 billion in 2023, with an average annual growth rate of 1.5%. The market has seen a steady rise, growing 5.3% annually since 2016. In 2023, Italy was ranked second in diabetes medicine sales, trailing Canada, which also recorded $1.5 billion. Following Italy in the rankings were Australia and Croatia, in third and fourth places, respectively. In terms of insulin exports, Italy is expected to reach $1.16 billion by 2028, up from $950 million in 2023, reflecting an annual growth rate of 3%. Since 1999, Italy's insulin supply has increased by 4.8% annually. In 2023, Italy held the third spot in global insulin exports, with France taking the lead at $950 million. France, Italy, and China were the top three insulin exporters that year. However, Italian insulin imports are set to decline, reaching approximately $138 million by 2028, down from $154 million in 2023, with an annual decrease rate of 2%. Since 1999, Italy's demand for imported insulin has decreased by 1.1% each year.

Marketing Banner

Italy Antidiabetics Market Data and Forecasts

How much will Italy Antidiabetics Market grow to 2028?

Forecast: Insulin in Dosage Market Size Value in Italy
Forecast: Export of Insulin in Dosage Forms from Italy
Forecast: Import of Insulin to Italy
Forecast: Import of Insulin in Dosage Forms to Italy
Forecast: Export of Insulin in Dosage Forms from Italy
More in Antidiabetics Industry for 2028